An Explosion of New Diabetes Treatments
Anne L. Peters, MD: Hi. I'm Dr Anne Peters. I'm here today with Dr Ele Ferrannini, who is a professor of medicine at the University of Pisa. Today we are going to tackle the difficult question of how to synthesize all that is new in the treatment of diabetes and how to make it practicable.
Why don't you tell us what your perspective is, an overview of what we have for treating diabetes that has come up in the past few years?
Eleuterio Ferrannini, MD, PhD: I think what is really striking about diabetes is that over a relatively short period of time, a number of new drugs and approaches have become available, whereas previously, the treatment and management of diabetes was essentially in a phase of stagnation. This is in contrast to what has been seen with hypertension, where there has been a steady development of new drugs over the course of time.
The other thing that is interesting is that there are multiple targets. It's not just the glucose or the glycated hemoglobin (A1c), but it's also the weight, the prevention of hypoglycemiaand correction of the basic pathophysiologic defects in diabetes. On the one hand, this should not be too surprising because we know that diabetes is a systemic, multifactorial, and polygenic disease.
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus Clinical Practice Guidelines (SID/AMD, 2022)
Pediatric Type 2 Diabetes Mellitus
COMMENTARY
Type 2 Diabetes Management: Choosing the Best Therapies
Anne L. Peters, MD; Eleuterio Ferrannini, MD, PhD
DisclosuresOctober 09, 2015
An Explosion of New Diabetes Treatments
Anne L. Peters, MD: Hi. I'm Dr Anne Peters. I'm here today with Dr Ele Ferrannini, who is a professor of medicine at the University of Pisa. Today we are going to tackle the difficult question of how to synthesize all that is new in the treatment of diabetes and how to make it practicable.
Why don't you tell us what your perspective is, an overview of what we have for treating diabetes that has come up in the past few years?
Eleuterio Ferrannini, MD, PhD: I think what is really striking about diabetes is that over a relatively short period of time, a number of new drugs and approaches have become available, whereas previously, the treatment and management of diabetes was essentially in a phase of stagnation. This is in contrast to what has been seen with hypertension, where there has been a steady development of new drugs over the course of time.
The other thing that is interesting is that there are multiple targets. It's not just the glucose or the glycated hemoglobin (A1c), but it's also the weight, the prevention of hypoglycemiaand correction of the basic pathophysiologic defects in diabetes. On the one hand, this should not be too surprising because we know that diabetes is a systemic, multifactorial, and polygenic disease.
Medscape Diabetes © 2015 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Type 2 Diabetes Management: Choosing the Best Therapies - Medscape - Oct 09, 2015.
Tables
References
Authors and Disclosures
Authors and Disclosures
Authors
Anne L. Peters, MD, CDE
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Served as a speaker or member of a speakers bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis
Eleuterio Ferrannini, MD, PhD
Professor of Medicine, University of Pisa, Pisa, Italy
Disclosure: Eleuterio Ferrannini, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; sanofi-aventis
Serve(d) as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; sanofi-aventis; Takeda
Received research grant from: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company